A Whole Blood Assay for AR-V7 and ARv567es in Patients with Prostate Cancer

Xichun Liu, Elisa Ledet, Dongying Li, Ary Dotiwala, Allie Steinberger, Allison Feibus, Jianzhuo Li, Yanfeng Qi, Jonathan Silberstein, Benjamin Lee, Yan Dong, Oliver Sartor, Haitao Zhang

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Purpose Most prostate cancer mortality can be attributed to metastatic castration resistant prostate cancer, an advanced stage that remains incurable despite recent advances. The AR (androgen receptor) signaling axis remains active in castration resistant prostate cancer. Recent studies suggest that expression of the AR-V (AR splice variant) AR-V7 may underlie resistance to abiraterone and enzalutamide. However, controversy exists over the optimal assay. Our objective was to develop a fast and sensitive assay for AR-Vs in patients. Materials and Methods Two approaches were assessed in this study. The first approach was based on depletion of leukocytes and the second one used RNA purified directly from whole blood preserved in PAXgene® tubes. Transcript expression was analyzed by quantitative reverse transcription-polymerase chain reaction. Results Through a side-by-side comparison we found that the whole blood approach was suitable to detect AR-Vs. The specificity of the assay was corroborated in a cancer-free cohort. Using the PAXgene assay samples from a cohort of 46 patients with castration resistant prostate cancer were analyzed. Overall, AR-V7 and ARv567es were detected in 67.53% and 29.87% of samples, respectively. Statistical analysis revealed a strong association of AR-V positivity with a history of second line hormonal therapies. Conclusions To our knowledge this is the first study to demonstrate that PAXgene preserved whole blood can be used to obtain clinically relevant information regarding the expression of 2 AR-Vs. These data on a castration resistant prostate cancer cohort support a role for AR-Vs in resistance to therapies targeting the AR ligand-binding domain.

Original languageEnglish (US)
Pages (from-to)1758-1763
Number of pages6
JournalJournal of Urology
Volume196
Issue number6
DOIs
StatePublished - Dec 1 2016
Externally publishedYes

Keywords

  • androgen
  • biomarkers
  • blood
  • prostatic neoplasms
  • protein isoforms
  • receptors
  • tumor

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'A Whole Blood Assay for AR-V7 and AR<sup>v567es</sup> in Patients with Prostate Cancer'. Together they form a unique fingerprint.

  • Cite this

    Liu, X., Ledet, E., Li, D., Dotiwala, A., Steinberger, A., Feibus, A., Li, J., Qi, Y., Silberstein, J., Lee, B., Dong, Y., Sartor, O., & Zhang, H. (2016). A Whole Blood Assay for AR-V7 and ARv567es in Patients with Prostate Cancer. Journal of Urology, 196(6), 1758-1763. https://doi.org/10.1016/j.juro.2016.06.095